Thank you for visiting Valeant’s Acquisition FAQs page. Here you will find links to the most up-to-date information on our acquisitions and other major business transactions. Please visit this page often as we will continue to update the information here on a consistent basis.
Acquisition of Obagi Medical Products, Inc. by Valeant
On April 25, 2013, Valeant Pharmaceuticals International, Inc. (“Valeant”) announced the completion of its acquisition of Obagi Medical Products, Inc. ("Obagi") following the expiration of the tender offer by Valeant to purchase all of the outstanding shares of Obagi for a price of $24 in cash, without interest (less any applicable withholding taxes). As a result of the merger, Obagi will become a wholly owned subsidiary of Valeant.
For more information, please click here for shareholder FAQs.
Acquisition of Medicis Pharmaceutical Corporation by Valeant
On December 11, 2012, Valeant Pharmaceuticals International, Inc. announced the completion of its acquisition of Medicis Pharmaceutical Corporation ("Medicis") following the approval of the transaction by stockholders of Medicis at the special meeting held on December 7, 2012. Valeant acquired all of the common stock of Medicis outstanding at the time of the completion of the acquisition, for $44.00 per share in cash.
For more information, please click here for shareholder FAQ's.
For questions regarding the impact to Medicis' Convertible Notes, please click on the corresponding links. These documents are intended as a summary only and are not a description of all the rights and obligations associated with these notes and the exercise of rights thereto.
Additionally, because the "Closing Price" of Medicis common stock, as defined under the indenture, has been fixed at $44.00 per share in connection with the merger, and such amount is greater than 110% of the conversion price of the 2032 Notes, the trading price condition to convertibility is met and holders may currently convert their 2032 Notes. The Company has issued a redemption notice to redeem all outstanding 2032 Notes on February 11, 2013 (the "Redemption Date") and accordingly, holders may convert their 2032 Notes at any time before 5:00 p.m., New York City time, on February 7, 2013, which date is two Business Days prior to the Redemption Date. After February 7, 2013, the 2032 Notes will no longer be convertible and any 2032 Notes that are outstanding thereafter will be redeemed on the Redemption Date as set forth in the redemption notice.
Readers are advised to review the applicable indentures for a more fulsome description.
Acquisition of Afexa by Valeant
In December 2011, Valeant Pharmaceuticals International, Inc. announced that the shareholders of Afexa Life Sciences, Inc. approved and completed the amalgamation of Afexa and Valeant's wholly-owned subsidiary. The amalgamation constitutes the subsequent acquisition transaction following the offer from the Offeror to acquire all the issued and outstanding common shares of Afexa and results in the privatization of Afexa.
For more information on this activity, please visit Afexa’s Chronology of Events page.
For questions regarding changes in Legacy Valeant certificates, please Shareholder Services page located in the Investor Relations section for information regarding out transfer agent.
In September 2010, the stockholders of Biovail Corporation and Valeant Pharmaceuticals International voted in favor of combining the two companies to become one under the Valeant name. The new combined company is known as Valeant Pharmaceuticals International, Inc. and its shares are traded on both the New York Stock Exchange and the Toronto Stock Exchange under the ticker symbol “VRX”.
- Please click here for the S-4 Prospectus.
- Please click here for Frequently Asked Questions (FAQs) for Shareholders.